作者
Silke Gillessen, Gerhardt Attard, Tomasz M Beer, Himisha Beltran, Alberto Bossi, Rob Bristow, Brett Carver, Daniel Castellano, Byung Ha Chung, Noel Clarke, Gedske Daugaard, Ian D Davis, Johann de Bono, Rodolfo Borges Dos Reis, Charles G Drake, Ros Eeles, Eleni Efstathiou, Christopher P Evans, Stefano Fanti, Felix Feng, Karim Fizazi, Mark Frydenberg, Martin Gleave, Susan Halabi, Axel Heidenreich, Celestia S Higano, Nicolas James, Philip Kantoff, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B Khauli, Gero Kramer, Chris Logothetis, Fernando Maluf, Alicia K Morgans, Michael J Morris, Nicolas Mottet, Vedang Murthy, William Oh, Piet Ost, Anwar R Padhani, Chris Parker, Colin C Pritchard, Mack Roach, Mark A Rubin, Charles Ryan, Fred Saad, Oliver Sartor, Howard Scher, Avishay Sella, Neal Shore, Matthew Smith, Howard Soule, Cora N Sternberg, Hiroyoshi Suzuki, Christopher Sweeney, Matthew R Sydes, Ian Tannock, Bertrand Tombal, Riccardo Valdagni, Thomas Wiegel, Aurelius Omlin
发表日期
2018/2/1
期刊
European urology
卷号
73
期号
2
页码范围
178-211
出版商
Elsevier
简介
Background
In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some of these topics.
Objective
To present the report of APCCC 2017.
Design, setting, and participants
Ten important areas of controversy in APC management were identified: high-risk localised and locally advanced prostate cancer; “oligometastatic” prostate cancer; castration-naïve and castration-resistant prostate cancer; the role of imaging in APC; osteoclast-targeted therapy; molecular characterisation of blood and tissue; genetic counselling/testing; side effects of systemic treatment(s); global access to prostate cancer drugs. A panel of 60 international prostate cancer experts developed the program and …
引用总数
20172018201920202021202220232024189213710178442816